Oramed CSO Kidron receives 19,000 vested shares

Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares.

Rhea-AI Filing Summary

Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares. On January 22, 2026, 19,000 PSUs vested after Oramed’s common stock reached a specified price level.

Each PSU converted into one share of common stock, so Kidron received 19,000 shares of Oramed common stock for no cash consideration. Following this equity-based award, she directly beneficially owns 1,448,664 shares of Oramed common stock, reflecting her ongoing equity stake in the company.

Insider Trade Summary

19,000 shares exercised/converted

Exercise 2 txns

Insider Kidron Miriam

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Exercise	Performance Stock Units	19,000	$0.00	$0.00
Exercise	Common Stock	19,000	$0.00	$0.00

Holdings After Transaction: Performance Stock Units — 0 contracts (Direct); Common Stock — 1,448,664 shares (Direct)

Footnotes (2)

1. F1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.
2. F2. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORMP’s Miriam Kidron report on this Form 4?

Miriam Kidron reported the vesting of 19,000 performance stock units into Oramed common shares. The vesting occurred when the stock achieved a specified price level, converting each unit into one share, and increased her directly held equity position without any cash changing hands.

How many Oramed (ORMP) shares does Miriam Kidron own after this transaction?

After the PSU vesting, Miriam Kidron directly beneficially owns 1,448,664 Oramed common shares. This total reflects the addition of 19,000 shares received from the vested performance stock units, which were granted earlier and became shares upon meeting performance conditions.

Did Miriam Kidron pay cash for the 19,000 Oramed (ORMP) shares received?

No, Miriam Kidron did not pay cash for these shares. The 19,000 Oramed common shares were received for no consideration when previously granted performance stock units vested after the company’s stock reached a specified price performance threshold, turning the PSUs into shares.

What triggered the vesting of Miriam Kidron’s Oramed (ORMP) performance stock units?

The vesting was triggered when Oramed’s common stock achieved a specified price per share. This performance condition caused 19,000 previously granted performance stock units to vest on January 22, 2026, each PSU converting into one share of common stock for Kidron.

What were the terms of the performance stock units reported by ORMP’s Miriam Kidron?

Each performance stock unit represented a contingent right to receive one Oramed common share. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 once the company’s stock price met the specified performance criteria, delivering 19,000 shares in total.

Is this Oramed (ORMP) Form 4 transaction a stock sale by Miriam Kidron?

No, this filing does not report a stock sale by Miriam Kidron. It records the vesting and conversion of 19,000 performance stock units into Oramed common shares, received for no cash consideration, increasing her direct share ownership rather than reducing it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kidron Miriam

(Last) (First) (Middle)

1185 AVENUE OF THE AMERICAS

THIRD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		M		19,000(1)	A	$0(1)	1,448,664	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/22/2026		M			19,000	(2)	(2)	Common Stock	19,000	$0	0	D

Explanation of Responses:

1. Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

2. Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.

	/s/ Miriam Kidron	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.